Background {#Sec1}
==========

OMVs secretion is a normal phenomenon during the growth of bacteria. OMVs are spherical, bilayered, membranous nanostructures (shown in Fig. [1](#Fig1){ref-type="fig"}). OMVs productions are not consistent in size, varying from approximately 20 nm to 250 nm. The parent bacterial membrane releases them and hence they contain numerous proteins, similar to parent bacteria \[[@CR1]--[@CR4]\]. Not only that, OMVs are demonstrated in abundance in bacterial components such as DNA \[[@CR5]\], RNA \[[@CR6], [@CR7]\], lipopolysaccharide (LPS) \[[@CR8]\], enzymes \[[@CR9], [@CR10]\], peptidoglycan \[[@CR11]\] and some molecules \[[@CR10]\]. Here, we enumerate some examples about virulence factors carried by OMVs (listed in Table [1](#Tab1){ref-type="table"}). These characteristics of OMVs endow with critical significance in pathogenesis and communication between bacteria and host cells. Recent studies have revealed that OMVs play fundamental roles in activating immune system and facilitate manifest responses against OMVs in the host \[[@CR12]\]. Despite of the increasing findings about effects of OMVs on host, innovative strategies based on OMVs have shown great potential in clinical implications and other relevant fields as we will discuss in this review.Fig. 1Visualization of the outer membrane vesicles about structures and components. Legend section: nucleic acid; virulence factor; protein; enzyme; peptidoglycan; outer membrane protein; lipopolysaccharide; outer membrane vesicles; outer membrane; periplasmic space; cytoplasmic membraneTable 1Important virulence factors found in bacterial outer membrane vesiclesParent bacteriumClassificationVirulence factorsDescriptionPutative functionsReferences*Pasteurella multocida*Gram negativeβ-lactamase (only found in Pm12945) OmpA, OmpH, OmpW, TbpEnzymes Proteins DNADisease pathogenesis, Deliver drug- resistant gene16Myxococcus xanthuGram negativeMepA, Several molecules with antibiotic properties, Hydrolytic enzymesProteins EnzymesHydrolytic function, antibiotic activities17*Bacteroides fragilis*Gram negativeB.fragilis toxin (BFT).proteasetoxin packaging and delivery18Vibrio choleraeGram negativeVrrA, OmpARNA, ProteinsOMVs regulation19Bacillus subtilisGram positiveLipoproteins, siderophore-binding proteinsProteinsbiosynthesis20Enterohemorrhagic *Escherichia coli* (EHEC)Gram negativeShiga toxin 2a, cytolethal distending toxin V, EHEC hemolysin, flagellinProteinscell cycle arrest and pathogenesis21

Simplified introduction of OMVs biological functions and biosynthesis {#Sec2}
=====================================================================

OMVs are not described useless as originally thought. Electron microscopy \[[@CR2]--[@CR4], [@CR10]\] and proteomic analyses \[[@CR1]--[@CR4]\] have confirmed OMVs are heterogeneous nanostructures packaging various bioactive components. They function as mediators to transmit biological information among different bacteria and host. For example, bacterial OMVs serve as nanovesicles to deliver important biological substances, which can promote the entry of bacterial antigens or even genes. Colitogenic *Bacteroides thetaiotaomicron* OMVs assist bacterial antigens access host cells in a sulfatase-dependent manner \[[@CR13]\]. Bacterial OMVs shoot short RNAs to boost the host-pathogen interaction \[[@CR6], [@CR7]\]. In addition, OMVs can act as a delivery system for virulence factors \[[@CR14]\] or antibiotic resistence genes \[[@CR15]\]. For instance, Bacteroides thetaiotaomicron OMVs carry cephalosporinases to protect gut pathogens against β-lactam antibiotics \[[@CR16]\]. Consequently, considering OMVs as effective vehicles to enhance the interactions between host and pathogen, the biosynthesis of OMVs deserve prominent attention to make us better understanding of OMVs as we will discuss below.

Interestingly, although both Gram-positive and Gram-negative bacteria have the capacity of producing OMVs \[[@CR17]\], the amounts of OMVs production and the components carried by OMVs are different with each other, even the same bacteria in different environment \[[@CR18], [@CR19]\]. Also, heterogeneous sized OMVs contain distinct protein profiles \[[@CR20]\].Usually, it is considered that OMVs production as responses to stress around bacteria to make bacteria survive and adapt within host \[[@CR18]\]. OMVs released from *Vibrio cholerae* appear heterogenous in size due to different culture environment and purification methods that affect chemical composition of OMVs as well \[[@CR21]\]. Ciprofloxacin-stimulated cultures produced more and larger vesicles which were enriched with cytosolic proteins compared with non-induced condition \[[@CR22]\]. Not just ciprofloxacin, antibiotic such as meropenem, fosfomycin, and polymyxin B can also increase production of OMVs \[[@CR23]\]. Furthermore, amounts of OMVs produced by cultured clean water bacteria increased upon treatmentwith ultraviolet radiation \[[@CR24]\]. *Pseudomonas putida* secrete OMVs in response to stress caused by cationic surfactants \[[@CR25]\]. There is a hypothesis that bacteria produce OMVs as defense mechanisms against external threats, including antibiotics \[[@CR26]\], antimicrobial peptides \[[@CR27]\], and bacteriophage infection \[[@CR28]\], which may enlighten us of the important role of OMVs in bacterial pathopoiesis. There are evidences indicating that *Porphyromonas gingivalis* (*P. gingivalis*) OMVs contribute to local immune evasion of *P. gingivalis* by hindering the host response \[[@CR29]\].

With the exception of the findings discussed above, many factors may be responsible for OMVs biosynthesis according to recent study: (1) Loss of some antigens of bacteria may contribute to proteins transformation in OMVs \[[@CR30]\] and virulence factor may regulate OMVs biogenesis \[[@CR31]\]. (2) Sandro et al., reported that the VacJ/Yrb ABC (ATP-binding cassette) transport system is involved in OMV formation among Gram-negative bacteria \[[@CR32]\]. Pseudomonas Quinolone Signal (PQS) is found to modulate OMVs production in *Pseudomonas aeruginosa* \[[@CR33]\]. On the basis of the discovery PQS, Alexander et al.*,* demonstrated reciprocal cross-species can induce OMVs biogenesis via secreted factors in Gamma proteobacteria but not included Alphaproteobacteria \[[@CR34]\]. (3) The formation of *Vibrio vulnificus* OMVs is associated with expression of the capsular polysaccharide \[[@CR35]\]. Enterohemorrhagic *Escherichia coli* OmpT have an impact on the biogenesis, composition, and size of OMVs \[[@CR36]\]. In addition, pathogenic or non-pathogenic bacterial OMVs may show great discrepancy in biological activity. Recent study reveals that toxigenic *Bacteroides fragilis* (*B. fragilis*) OMVs represent different metabolic activities compared with nonpathogenic *B. fragilis* OMVs \[[@CR37]\]. In addition, emerging evidences indicate that close relationships between bacterial components and OMVs may modulate production of OMVs.Wael et al. declared that LPS remodeling leads to formation of OMVs in *Salmonella* \[[@CR38]\]. Contrarily, *Salmonella* OMVs can also accelerate LPS remodeling during environmental transitions \[[@CR39]\]. Haruyuki et al.*,* found if DNA inversion occur in *B. fragilis*, it will regulate the formation of OMVs \[[@CR40]\], and small RNAs may modulate the composition of outer membrane proteins, which may be critical to OMVs synthesis \[[@CR41]\]. In conclusion, these innovative findings have expanded our knowledge of how OMVs generate from parent bacteria. We can speculate from so many evidences about OMVs production that whether OMVs serve as a mirror reflecting the surrounding environment around bacteria and the real time condition of bacteria or not. If it is right, we can evaluate the level of bacterial condition through quantitative analysis of OMVs, which may be a promising idea concerning monitoring the growth of bacteria involved in related fields. However, the mechanisms of OMVs formation have not been explored clearly, no unanimous conclusion can be made in this field. It deserves more attention and more research to find the truth concealed behind the phenomenon.

Interactions of bacterial OMVs with host cells {#Sec3}
==============================================

Despite the mystery on the mechanisms involved in OMVs formation, the research on the functions of bacterial OMVs especially with host cells keep growing rapidly. Next, we will focus on the correlation between bacterial OMVs and host cells, mainly including the OMVs entry mechanisms of host cells together with the effects of OMVs on host cells.

How can host cells uptake OMVs? {#Sec4}
-------------------------------

Bacterial OMVs are recognized as external foreign matters by host cells. Considering OMVs carry numerous components of their parent bacteria, are they responsible for the entry of OMVs into host cells? It is widely accepted that several main pathways may promote the entry of OMVs including macropinocytosis \[[@CR20]\], lipid raft-dependent or lipid raft-independent endocytosis, and clathrin- \[[@CR42]\], caveolin- \[[@CR20]\] and dynamin-dependent \[[@CR43]\] entry (reviewed in REF47). Recent study may expand our knowledge of this topic. Sivapriya et al.*,* show clear evidences that bacterial OMVs deliver LPS into host cells via endocytosis, then LPS released from early endosomes into cytosol to induce the activation of caspase-11 and the secretion of inflammatory cytokines \[[@CR44]\]. LPS structure especially the O antigen structural region is critical to OMVs entry. OMVs lacking O antigen may use clathrin-mediated endocytosis as a main route of entry nevertheless OMVs with intact O antigen are mediated by raft-dependent pathways \[[@CR45]\]. *Helicobacter pylor* OMVs size can determine their mechanisms of host cells entry \[[@CR20]\]. Moreover, bacterial OMVs express pathogen associated molecular patterns (PAMPs) on their surface. It may activate TLR signaling to facilitate OMVs entry into host cells. Lan et al.*,* argues that the activation of toll like receptor 4 (TLR4) contribute to OMVs deliver LPS into cytosol \[[@CR46]\]. *Legionella pneumophila* OMVs membrane fuse with eukaryotic membrane systems, which may deliver pathogen factors to host cell membranes \[[@CR47]\]. In brief, bacterial OMVs have their specific routes to host cells and the properties of OMVs may affect their decision about which road to choose when they asses into host cells. Anyway, OMVs can enter into host cells via different manners so that they can arouse strong response to cells as discussed below.

Impressive effects of OMVs on host cells {#Sec5}
----------------------------------------

Bacterial OMVs bleb from bacterial outer membrane, amounts of proteomics and chemical analysis show that they carry plenty of virulence factors coming from bacteria as we have discussed before \[[@CR48]--[@CR51]\]. Hence, OMVs inherit similar immunogenicity to parent bacteria. When OMVs are utilized to examine the reaction of host cells, meaningful results come out. Next, we will focus on the discussion about the OMVs interactions with host cells and review the recent study on the field.

Usually, OMVs invade into host cells and bypass the epithelial cells barrier. Then, they will be exposed to innate immune cells mainly including neutrophils, macrophages and dendritic cells resident in submucosa and these immune cells will be activated to elict inflammatory responses against OMVs. In addition, adaptive immune cells involved in B cells and T cells will be awaked by signal molecules released from antigen presenting cells (APCs). In summary, the interactions between OMVs and immune cells (shown in Fig. [2](#Fig2){ref-type="fig"}) are manifested and this will be elucidated separately.Fig. 2Brief illustration about interactions involved in OMVs and main immune cells. Legend section: stress; bacterium; outer membrane vesicles; neutrophils; dendritic cells; chemokines; cytokines; antibody

### OMVs with neutrophils {#Sec6}

Although OMVs are considered as non-duplicate, inanimate form nano structures, they can activate neutrophils to induce inflammatory cytokines in host. For example, *Neisseria meningitidis* associated OMVs simulate human neutrophils to produce pro-inflammatory profile of cytokines and chemokines including interleukin1-β (IL1-β), IL-8, tumor necrosis factor alpha (TNF-α), macrophage inflammatory protein 1α (MIP-1α), and MIP-1β \[[@CR52]\]. Further study demonstrate gamma interferon (IFN-γ) can improve the level of these cytokines to maintain the condition of chronic inflammation \[[@CR52]\]. These responses are similar to neutrophils triggered by bacterial infection, it appears that OMVs can contribute to protective immunity against infection. On the contrary, some bacterial virulence factors carried by OMVs can inhibit the antimicrobial activity of neutrophils and hence contribute to attenuate the secretion of cytokines simulated by OMVs. For example, uropathogenic *Escherichia coli* (UPEC) OMVs carry cytotoxic necrotizing factor type 1 (CNF1). CNF1 are recognized as toxin that can decrease the membrane fluidity of polymorphonuclear leukocytes (PMNs), which may contribute to functional impairment of PMNs and hence decreased profile of cytokines and chemokines \[[@CR53]\]. Despite of the demonstration of OMVs effects on neutrophils, novel opinions appear that *Neisseria meningitidis* OMVs can be neutralized by plasma and bactericidal/permeability-increasing protein (BPI) and the neutrophils disable to clean the production of OMVs \[[@CR54]\].

In contrast, pathogens are responsible for the death of neutrophils. When neutrophils try to prevent the invasion of bacteria, they will sacrifice themselves to trigger killing defense mechanism against pathogens. Neutrophil extracellular traps (NETs) are a novel bacterial killing mechanism that enable neutrophils clean pathogen rapidly \[[@CR55]\]. Bacterial OMVs are reported that they can induce NETs formation as well \[[@CR56]\]. However, *Neisseria meningitidis* can escape NETs involved innate response, which may increase the amounts of OMVs and promote the progression of infection \[[@CR56]\]. We can summarize from the discussion above that neutrophils show great discrepancies in immune response to bacterial OMVs.

### OMVs with macrophages {#Sec7}

Macrophages act as a classical type of immune cells, they can elicit potent immune responses when they are treated with bacterial OMVs. Firstly, OMVs enforce macrophages to secrete pro-inflammatory cytokines. OMVs pretreatment evoked inflammatory responses in macrophages \[[@CR3], [@CR57]--[@CR59]\]. Bacterial OMVs are phagocytosed by macrophages and activated macrophages then induce increased production of TNFα, IL-8, and IL-1βthrough NF-κB activation \[[@CR60]\]. Macrophages simulated with *P. gingivalis* OMVs produce more TNFα, IL-12p70, IL-6, IL-10, IFNβ, and nitric oxide \[[@CR61]\]. Isolated *Legionella pneumophila* (*L.pneumophila*) OMVs have the pro-inflammatory potential on macrophages dependent on TLR2/4 pathway \[[@CR62]\]. Furthermore, OMVs facilitate *L. pneumophila* replication in macrophages. The finding may explain OMVs promote spreading of *L. pneumophila* in the host \[[@CR63]\]. Guanylate Binding Proteins (GBP) are demonstrated as regulators of OMVs-mediated inflammation when using avirulent *Escherichia coli* OMVs to infect bone marrow-derived macrophages (BMDMs) \[[@CR64]\]. However, porin loss OMVs may elicit lower levels of proinflammatory cytokine secretion compared with *Klebsiella pneumoniae* OMVs with porin \[[@CR65]\]. Secondly, macrophages simulated by bacterial OMVs may cause adaptive immune response. *Neisseria meningitidis* \[[@CR66]\] or *Klebsiella pneumoniae* \[[@CR67]\] OMVs upregulate the expression of molecules supporting antigen presentation on the surface of macrophages, for example, [cluster of differentiation](https://en.wikipedia.org/wiki/Cluster_of_differentiation) 80(CD80), major histocompatibility complex-II (MHC-II), CD86 \[[@CR59]\], human leukocyte antigen-DR (HLA-DR), and intercellular adhesion molecules-1(ICAM-1). As one of the professional antigens presenting cells, macrophages enable to simulate T cells to recognize OMVs antigens and then promote adaptive immune response. Naive peritoneal macrophages treated with *Shigella boydii* OMVs can trigger polarization of CD4+ T cells toward Th1 adaptive immune response \[[@CR58]\]. Thirdly, bacterial OMVs can make macrophages metabolic remodeling and induce pyroptosis \[[@CR61]\] and apoptosis \[[@CR68]\] as reported. These effects on macrophages may contribute to decreased amounts and dysfunction of protective cells, which may be considered as an important factor leading to diseases in host body.

With the exception of inflammatory role in macrophages, bacterial OMVs can play anti-inflammatory roles in infected host cells. Previous findings have revealed that macrophages treated with OMVs will secrete more anti-inflammatory cytokines such as IL-10 \[[@CR58], [@CR61]\]. *Helicobacter pylori* OMVs lead to more production of immunosuppressive cytokine IL-10 by human peripheral blood mononuclear cells (PBMC) and apoptosis in Jurkat T cells \[[@CR69]\]. Accordingly, it can be considered that on the one hand, bacterial OMVs elicit potent immune response against infection, and on the other hand, they benefit bacteria by limiting the inflammation and destroying immune cells to promote bacterial survival in the host. It seems like double-edged sword as to host hence we need to make best use of the advantages and bypass the disadvantages of OMVs by exploring effective instructions about them.

### OMVs with dendritic cells {#Sec8}

Similarly, bacterial OMVs can activate dendritic cells by upregulating the expression of co-stimulatory molecules and inducing the cytokines profile \[[@CR70]\]. Meningococcal OMVs have the capacity of stimulating dendritic cells by inducing high expression of the CD40, Programmed death-ligand 1(PD-L1), CD83, CD80, CD86, and HLA-DR activation markers. Meanwhile, dendritic cells stimulated by Meningococcal OMVs produce more cytokines such as IL-6, IL1β compared with un-stimulated dendritic cells \[[@CR71]\]. *Helicobacter pylori* OMVs induce dendritic cells to express more Heme Oxygenase-1 via activating Akt-Nrf2 and mTOR-κB Kinase--NF-κB pathways \[[@CR72]\]. Collectively, exposure of dendritic cells to bacterial OMVs may trigger innate immune response against bacterial infection \[[@CR73]--[@CR79]\]. As professional APCs, the up-regulation of the co-stimulatory molecules expression have critical significance in triggering adaptive immune response as will be discussed next.

### OMVs with B cells {#Sec9}

It is well acknowledged that B cells mediate humoral immunity via mainly secreting antibody such as immunoglobulin (Ig) to protect host from pathogen infection. Usually, B cells require assistance of T cells to response to external antigen. *Salmonella typhimurium* OMVs activate prime B cells response together with T cells and the specific IgG can be detected in mice immunized with OMVs \[[@CR59]\]. Conversely, OMVs can directly simulate B cells response without the help of T cells \[[@CR80]\]. Furthermore, the activity of proliferation will be potentiated by OMVs simulation and the B cell receptor (BCR) may be a prerequisite for this mitogenic response \[[@CR80]\]. *Neisseria lactamica* can induce the secretion of polyclonal IgM by B cell proliferation, resulting in colonizing and immune tolerance in host without adaptive immune response \[[@CR81]\]. To explore the interaction between OMVs and B cells, a novel mechanism may explain the activation of B cells by bacterial OMVs. *Moraxella catarrhalis* produce OMVs to help them escape from host immune response \[[@CR82]\]. The author clarifies the procedure of how B cells respond to OMVs. First, BCR internalization and then IgD BCR clustering and Ca^2+^ mobilization will be triggered on the membrane of activated B cells. Then, some motifs including IgD-binding super antigen MID, unmethylated CpG-DNA are critical for activation. At last, the production of IL-6 and IgM together with increased expression of surface marker (HLA-DR, CD45, CD64, and CD86) follow by activation CD19^+^ IgD^+^ lymphocytes \[[@CR82]\]. In conclusion, OMVs have widespread effects on B cells as one important part of adaptive immune response.

### OMVs with T cells {#Sec10}

When OMVs gain access into host, APCs present OMVs antigen to CD4^+^T cell and then facilitate T helper cell (Th) differentiation into mainly three subtypes including Th1, Th2, Th17, which contribute to cell immune response together with humoral immune response. On the basis of the theory, OMVs show potential adjuvant effects on T cells cross-priming involved in CD4^+^T cell response and CD8^+^T cell response \[[@CR83]\]. In brief, OMVs can elicit potent protective immune responses, which may make OMVs become effective vaccines candidate.

However, recent study shows that OMVs may suppress T cell response and proliferation via various manners. For example, *Neisseria meningitidis* OMVs carried Opa proteins could affect T cell proliferation by changing receptor binding \[[@CR84]\]. Helicobacter pylori OMVs are demonstrated to inhibit T cell proliferation through inducing the COX-2 expression in monocytes \[[@CR85]\]. In addition, *Neisseria gonorrhoeae* PorB presenting in OMVs can suppress CD4^+^T cell proliferation while PorB proteosomes can alter the immunosuppression \[[@CR86]\]. The negative effects on immunity may contribute to bacterial survival and invasion, which should be highlighted to learn more about pathogenicity of bacteria.

### OMVs with other host cells {#Sec11}

Except the effects of OMVs on immune cells, numerous cells can respond to OMVs as we will discuss below. There are reports that bacterial OMVs can also induce morphological changes in host cells \[[@CR87], [@CR88]\]. Meanwhile, similar to the effects on immune cells, OMVs can induce inflammatory responses when they are exposed to host cells. *Stenotrophomonas maltophili* OMVs elicit a potent inflammatory response in human lung epithelial A549 cells \[[@CR89]\]. *Vibrio cholerae* OMVs are responsible for inflammatory responses via secreting biologically active proteases \[[@CR90]\]. *Pseudomonas aeruginosa* OMVs activate inflammasome through caspase-5 in human THP-1 monocytes \[[@CR91]\]. *Escherichia coli* derived OMVs can elicit immune response \[[@CR92]\] and promote interleukin 8 production in human intestinal epithelial cells \[[@CR93]\]. However, the interactions are complicated and different between various OMVs and species. *Acinetobacter baumannii* OMVs show phospholipase, hemolytic and leucotoxic activities when treated with red blood cells and white blood cells \[[@CR94]\]. *Helicobacter pylori* OMVs play an important role in eosinophil degranulation \[[@CR95]\]. Bacterial OMVs- associated DNA can internalize by epithelial cells, which may suggest important role of OMVs in host-pathogen interactions \[[@CR5]\]. *Aggregatibacter actinomycetemcomitans* OMVs are internalized in human embryonic kidney cells and trigger innate immune response \[[@CR11]\]. *P. gingivalis* OMVs can promote calcification of vascular smooth muscle cells through ERK1/2-RUNX2 \[[@CR96]\] and initiate innate immune responses of human endothelial cells \[[@CR97]\]. Probiotic *Escherichia coli* OMVs contribute to the reinforcement of the epithelial barrier by regulating expression of tight junction proteins in intestinal epithelial cells \[[@CR98]\].A similar strategy is utilized by *Escherichia coli* to strengthen the leukocyte binding on endothelial cells, as OMVs increase the expression of functional cell adhesion molecules \[[@CR99]\]. On the contrary, *Pseudomonas aeruginosa* OMVs induced by human mucosal fluid and lysozyme can compromise an epithelial barrier \[[@CR100]\].*Campylobacter jejuni* OMVs have proteolytic activity to clean intestinal epithelial cell E-cadherin and occludin \[[@CR101]\]. We can draw a conclusion from the reports above that bacterial OMVs may be responsible for the interactions of pathogen with intestinal epithelial cells.

### OMVs associated with apoptosis in host cells {#Sec12}

Despite of bonus bring from OMVs, OMVs shed from bacteria can directly induce host cells apoptosis due to the virulence factors inside OMVs \[[@CR4]\]. Host cells treated with EHEC O157 OMVs develop G2 cell cycle arrest and the study proves OMVs can serve as carriers of EHEC O157-mediated host injury \[[@CR102]\]. At the same time, OMVs associated with the probiotic *Escherichia coli* lead to DNA damage in intestinal epithelial cells \[[@CR42]\]. The outbreak strain *Escherichia coli* O104:H4 derived OMVs carry virulence factors will cause apoptosis of human intestinal epithelial cells \[[@CR43]\]. OMVs from *Neisseria gonorrhoeae* target PorB to mitochondria and induce apoptosis \[[@CR6]\]. *Acinetobacter baumannii* omp33--36 porin induces apoptosis and modulates autophagy in *HeLa* and HEp-2 cells \[[@CR103]\]. *Acinetobacter nosocomialis* produce OMVs to induce cytotoxicity of epithelial cells \[[@CR104]\]. These evidences clearly show cell injury and decreasing amounts of cells during the period of bacterial infection, which may promote the spread of bacteria and damage host defense system against infected bacteria.

Application of bacterial OMVs as vaccines {#Sec13}
=========================================

OMVs possess several inherent characteristics that make them consider as a potential vaccine candidate. (1) OMVs remain intact and steady at different temperatures and treatments \[[@CR18], [@CR21], [@CR105]\]. Considering the properties, OMVs are designed as storage containers to protect enzymatic function \[[@CR106]\]. (2) they have inanimate activity, non-replicative property and adjuvant effect \[[@CR105]\], but they contain substantial immunogenic components \[[@CR1]\] associated with parent bacteria, which may elicit potent innate and adaptive immune responses against bacterial infection \[[@CR73]--[@CR79]\]. Shiga toxin-producing *Escherichia coli* (STEC) OMVs can be treated as vaccines to protect mice and claves against Hemolytic Uremic Syndrome (HUS) \[[@CR106]\]. OMVs derived from *Bordetella bronchiseptica* can survive mice from sublethal infection \[[@CR107]\]. *Salmonella enteritidis* OMVs provide strong protective efficiency against *S. enteritidis* infection \[[@CR108]\]. In addition, OMVs are multipurpose so that they can be engineered as vehicles to carry any antigens or anything else. Yoshihiro Ojima et al.*,* packaged green fluorescence protein (GFP) into the OMVs of *Escherichia coli* and succeed to express OmpW-GFP recombinant protein in OMVs \[[@CR109]\]. Engineer OMVs deliver surface-associated glycotopes to the immune system and then induce protective antibody \[[@CR110]\]. *Neisseria meningitidis* OMVs modified by genetic technique show stronger immune response than native OMVs \[[@CR111]\]. Moreover, they can be modified by special technology to reduce their toxicity and become safe to host. To our knowledge, OMV-based meningococcal vaccine is the only implication of OMVs for clinical trial to control a clonal B outbreak so far \[[@CR112], [@CR113]\]. However, because vaccines derived from OMVs are infancy and strategies are immature (shown in Table [2](#Tab2){ref-type="table"}). Vaccines made of OMVs require more time and efforts to be licensed for human use even if amounts of researches have proved their efficiency in animal model (shown in Table [3](#Tab3){ref-type="table"}).Table 2Limitation of vaccines based on bacterial OMVsParent bacteriaLimitationResolventReferencesSTEC strain (O157:H7 serotype)Efficiency restricted to O157:H7 serotypemulti-antigenicity vaccines need to be explored85*S. Enteritidis*Slightly toxicityImproved stratgies to reduce endotoxin activity87*E. coli*verification of protection effects only in miceFurther evaluation on other species93*Neisseria meningitidis*Short duration when immunization beyond the vaccine strainRepeat immunization and adapt other components of vaccines to OMVs91*Neisseria meningitis*the safety need to be considered because of potent immune responseVaccination with aluminum hydroxide to ensure safety95*V. cholerae*LPS endotoxicity and expensive production of OMVsRecombinant OMVs to reduce endotoxicity and advanced methods on OMVs isolation99Abbreviations: *STEC*, Shiga toxin-producing Escherichia coli; *OMVs*, outer membrane vesicles; *S. Enteritidis*, Salmonella Enteritidis; *E.coli*, Escherichia coli; *V. cholerae*, Vibrio cholerae; *LPS*, lipopolysaccharide;Table 3Evaluations of immune protective response mediated by bacterial OMVs against infection in mice modelParent bacteriaModel establishmentOMVs administrationAdjuvant usedEfficiencyImmune responseReferences*E. coli*porcine pleuropneumoniasubcutaneousaluminum87.5% survival for APP serotype 7Serum IgG Th1 and Th2 cytokines secretion9362.5% survival for APP serotype 1S. Enteritidisfoodborne infections of S. Enteritidisintranasal or intraperitonealnone83.3% survival intranasallySerum IgG and secretory IgA8791% survival intraperitoneallySalmonella entericaOral infectionIntranasally or intraperitoneallynone100% survival by Intraperitoneal immunizationSerum IgG and mucosal IgA9480% survival by intranasal immunizationNeisseria meningitisInfectionsubcutaneousaluminum hydroxide100% survivalSerum IgG95Neisseria meningitidisHealthy neonatal miceintranasal and subcutaneousDODAB-BF and aluminum hydroxideNot mentionedIgG, Intranasal immunization, Th1 and Th2 response,96Th1 profile for subcutaneous immunizationP. gingivalisInfectionintranasalPoly (I:C)Not mentionedSerum IgG (including IgG1 and IgG2a) salivary S-IgA84*K. pneumoniae*Sepsisintraperitonealnone80% survival with 0.5 μg OMVs and 100% survival with 1 μg OMVsSerum IgG and the secretion of key cytokines of Th1 cells (IFN-γ)62B. pseudomalleiSepticemic infectionsubcutaneousnone100% survival compared with40% survival in naive miceserum IgG (IgG1, IgG2a, and IgG3) and IgM97Bordetella pertussisInfectionintraperitonealnoneNot mentionedserum IgG, Th1 and Th17 response (the classic whole cell vaccine)98Th1/Th17 and Th2 mixed response (acellular vaccines)V. choleraeInfectionOral immunizationnone\> 80% protectionserum IgG, IgA, IgM, mucosal sIgA, Th2 and Th17 cell response99Shigella boydiiInfectionOral immunizationnone100% protectionmucosal IgG and IgA, Th1 cell response54*B. abortus*InfectionsubcutaneousFreund's complete and incomplete adjuvantNot mentionedSerum IgG, cellular immune response100Abbreviations: *E.coli*, Escherichia coli; *APP*, Actinobacillus pleuropneumoniae; *S. Enteritidis*, Salmonella Enteritidis; *Th*, T helper;*P. gingivalis*, Porphyromonas gingivalis;*Ig*, immunoglobulin; *K. pneumoniae*, *Klebsiella pneumoniae*;*B. pseudomallei*, Burkholderia pseudomallei; *V. cholerae*, Vibrio cholerae; *B. abortus*, Brucella abortus; Infection means mice challenged with the same bacteria if not specific statement

Conclusion {#Sec14}
==========

Bacterial OMVs were discovered almost half a century ago, scientists have never desisted from exploring the mechanisms and effects about OMVs. According to the recent study, despite of obscure mechanisms regarding to OMVs formation, we have a better understanding of the mechanisms of OMVs entry, which may enlighten us of how OMVs communicate with host cells. However, a mode of OMVs entry cannot be adopted by all bacteria and we wonder if there is a common way that OMVs can take. Plenty of evidences elucidate the significant effects of OMVs on host cells. We can summarize that OMVs can drive host cells to produce more pro-inflammatory and anti-inflammatory cytokines in response to OMVs challenge. Meanwhile, innate and adaptive immune response can be imitated by exposure to OMVs. In contrast, OMVs have the capacity of inhibiting immune cells responses \[[@CR69], [@CR85]\] which may contribute to bacteria survival and spread. It seems that OMVs can play dual role in modulating immune system response against infection (shown in Fig. [3](#Fig3){ref-type="fig"}). Together with the responses caused by OMVs, OMVs may play an important role in bacterial pathogenesis and the interactions between pathogen and host cells. There is one report regarding OMVs in indoor dust elucidating the association between asthma with OMVs, which may remind us that OMVs may have a broader effect on inflammatory \[[@CR114]\].Fig. 3Double-edged effects of OMVs in host. Legend section: protection; destruction; proliferation; immunoglobulin; cytokines; immune activation; immunosuppression; apoptosis

Furthermore, OMV-based vaccines show great potential in the development of immunity to diseases caused by bacteria. Innovative technologies make bioengineered OMVs possible to serve as specific vaccines targeted on limited pathogen \[[@CR115]\]. Enlightened from the technologies, scientists utilize modified OMVs just as a vehicle to carry drugs or anything else if they want to evaluate the effects on other diseases even cancer, which broad the therapeutic implications and expand the field of OMVs applications, not just restricted to bacterial infection. For instance, bacterial OMVs are engineered as multi-functional nanodevices for biosensing and bioimaging of cancer cells \[[@CR116]\]. OMVs decorated with tumor-specific epitopes can induce strong inhibition of tumor growth \[[@CR117]\]. Collectively, advances are made to expand our knowledge of exploiting OMVs-associated techniques to benefit the health of human worldwide.
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